OMER at a glance
OMEROS CORP (OMER, SEC CIK 1285819) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 13, 2026 and Form 4 insider filings as recently as September 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding OMEROS CORP (OMER) shares worth $155.1 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Borges David J. on September 23, 2026 of 10,000 shares at $20.95 per share.
- In the last 90 days, OMER insiders reported 0 open-market purchases ($0) and 11 open-market sales ($2.2M) on Form 4, a net sale of $2.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 11 sells
- Net −$2.2M
- 13F holders
- 25 funds
- $155.1M · −3 vs prior quarter
- Latest 8-K
- Aug 13, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Product sales $28.5M vs $0 YoY, reflecting YARTEMLEA launch and physician adoption
- Gross margin 97.2%, based on $28.5M revenue and $0.8M product costs
- R&D expense $13.8M vs $22.0M YoY; SG&A $13.9M vs $10.3M
- Cash, equivalents and short-term investments $132.0M; operating cash flow $4.1M
- Q3 R&D and SG&A expected higher, driven by YARTEMLEA and OncotoX-AML investment
Risk Factors
- Newly added risk: $100.0 million share-repurchase program authorized in November 2025
- Most material update: 488,716 shares repurchased at $11.70 average during the quarter
- Market risk: Repurchases could increase volatility, reduce liquidity, or precede stock-price declines
- Regulatory risk: Program suspension or termination remains subject to corporate and regulatory requirements
- Financial risk: $90.1 million remained available for future repurchases as of August 12, 2026
AI summary of the OMER 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded to nine directors with Joseph Schocken appointed effective August 12, 2026
- Schocken joins the Audit Committee, adding investment banking and public-company governance experience
Item 2.02: Results of Operations and Financial Condition
- Omeros reported financial results for the three and six months ended June 30, 2026
- Detailed results and management commentary provided in Exhibit 99.1 press release
Item 8.01: Other Events
- $14.5M principal Notes repurchased July 20, 2026 for approximately $29.0M including interest and obligations
- Total Notes retired increased to $30.5M through privately negotiated transactions
AI summaries of OMER 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for OMER
Don't miss the next OMER filing
- Alerts as it files. A push when OMER files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut OMER, by share count.
- Ask anything. An AI agent that reads every OMER filing and answers with sources.
OMER alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Borges David J. | Sell | Sep 23, 2026 | 10,000 | $20.95 |
| Borges David J. | M | Sep 23, 2026 | 10,000 | - |
| Borges David J. | M | Sep 23, 2026 | 10,000 | $15.58 |
| Borges David J. | Sell | Sep 22, 2026 | 10,000 | $20.95 |
| Borges David J. | M | Sep 22, 2026 | 5,000 | - |
| Borges David J. | M | Sep 22, 2026 | 5,000 | $2.94 |
| Borges David J. | M | Sep 22, 2026 | 5,000 | $3.93 |
| Borges David J. | M | Sep 22, 2026 | 5,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$164.5M | -$169.3M | -$122.8M |
| Net Income | -$117.8M | -$156.8M | -$3.4M |
| Balance Sheet | |||
| Total Assets | $378.3M | $277.1M | $325.6M |
| Equity | -$25.0M | -$182.6M | -$121.2M |
| ROE | 471.6% | 85.9% | 2.8% |
| Per Share | |||
| EPS | - | $-2.70 | $-0.05 |
| Cash Flow | |||
| Operating CF | $74.7M | -$148.8M | -$116.1M |
| CapEx | $426K | $165K | $65K |
Source: XBRL data in OMEROS CORP (OMER)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate OMER share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $155.1M |
| Q1 2026 | 28 | $151.1M |
| Q4 2025 | 24 | $267.7M |
| Q3 2025 | 24 | $70.3M |
| Q2 2025 | 25 | $44.7M |
| Q1 2025 | 22 | $77.7M |
| Q4 2024 | 18 | $76.2M |
| Q3 2024 | 13 | $16.4M |
- BlackRock+735.0K (+14%)
- Invesco Ltd+571.1K (+316%)
- State Street Corp+400.3K (+21%)
- Vanguard Portfolio Management LLC+244.2K (+34%)
- Northern Trust+163.5K (+29%)
- Citadel Advisors LLC−174.5K (-67%)
- Millennium Management−66.8K (-16%)
- Goldman Sachs Group−45.9K (-23%)
- Bank of America Corp−10.7K (-5%)
- FMR LLC (Fidelity)−3.0K (-16%)
- Dimensional Fund Advisors−179.6K
- D.E. Shaw & Co−71.2K
- Raymond James Financial−10.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 179 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
OMER filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 8-K | Jul 20, 2026 | - | Analysis | - |
| 8-K | Jul 6, 2026 | - | Analysis | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 4 | May 27, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
OMER SEC filings: frequently asked questions
Are OMER insiders buying or selling?
In the last 90 days, OMEROS CORP (OMER) officers, directors and 10% owners reported no open-market purchases and 11 open-market sales worth $2.2 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold OMER stock?
As of June 30, 2026, the largest OMEROS CORP (OMER) holders among the 13F filers tracked by SignalX were BlackRock ($57.5 million), Vanguard Capital Management LLC ($29.2 million), State Street Corp ($22.1 million), Vanguard Portfolio Management LLC ($9.2 million), Invesco Ltd ($7.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did OMER report in its latest 8-K?
OMEROS CORP (OMER) filed an 8-K on August 13, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Board expanded to nine directors with Joseph Schocken appointed effective August 12, 2026.
What are the latest OMER SEC filings?
OMEROS CORP (OMER) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 13, 2026 and a Form 4 insider filing on September 24, 2026.
What is OMER's SEC CIK number?
OMEROS CORP (OMER)'s SEC Central Index Key (CIK) is 1285819. EDGAR lists every OMER filing under that number.
Ask anything about OMER
The research agent reads OMER's filings, financials, insider trades and 13F holders, then answers with sources.